How is Rituxan Hycela administered?
Rituxan Hycela (rituximab and hyaluronidase human) is given via subcutaneous injection - an injection under the skin - in the stomach area. It is administered by a healthcare professional.
Rituxan Hycela contains rituximab, the same active ingredient as in Rituxan. But it has been formulated so that it can be given over 5-7 minutes via subcutaneous injection, rather than via intravenous (IV) infusion like Rituxan, which can take 3-6 hours.
Rituxan Hycela should only be administered after at least one full dose of a rituximab product has been administered via intravenous (IV) infusion because of the potential for hypersensitivity reactions and other side effects during the initial administration of rituximab products.
Before you receive Rituxan Hycela, an antihistamine and acetaminophen, and possibly a glucocorticoid medication, will be administered to help prevent side effects. After your injection you’ll be monitored for at least 15 minutes.
References
- Rituxan Hycela website. Prescribing information. Administration. [Accessed September 29, 20201]. Available from: https://www.rituxanhycela.com/hcp/dosing-and-administration/administration.html.
- NIH, National Cancer Institute. New Rituximab Formulation Approved for Some Lymphomas, Leukemia. July 14, 2017. [Accessed September 29, 2021]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-rituxan-hycela.
Read next
What is the success rate of Breyanzi?
Everyone will respond differently to Breyanzi (lisocabtagene maraleucel), and the success rate for someone else may be different than for you. Based on clinical trial data, the complete response rate in patients taking Breyanzi is around 20% to 73%, depending on the condition being treated. Continue reading
What is the survival rate of Kymriah?
Studies are ongoing to monitor the survival rate of patients who received Kymriah (tisagenlecleucel) as a cancer treatment. Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell advanced B-cell acute lymphoblastic leukemia is 55%. Continue reading
What's the difference between Kymriah and Yescarta?
Kymriah and Yescarta are two cell-based gene therapies. A few differences between the two medications include who and what they are FDA approved for, their dosage, and which companies make them. Continue reading
Related medical questions
- What is the difference between Rituxan and Rituxan Hycela?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- What is the difference between Truxima and Rituxan?
- Does Truxima make you gain weight?
- What are the names of the BTK inhibitors?
- What is the cost of Kymriah?
- What is Zydelig used for and how does it work?
- What is the success rate of Epkinly?
- What type of drug is Copiktra?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- Prednisone: What are 12 Things You Should Know?
- What is the success rate of Monjuvi?
- What causes infusion reactions to rituximab?
- How does Monjuvi work?
- How is Monjuvi given / administered?
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
- How long does it take for Jaypirca to work?
- How does the drug Rituxan work?
- Is Venclexta (venetoclax) chemotherapy?
- How do you prepare for a Rituxan infusion?
- Does ibrutinib cause hair loss?
- How effective is Venclexta?
- How long do you take Venclexta for?
- Is Truxima a chemotherapy drug?
- How is Arzerra administered and how long to work?
- Is Zydelig a chemotherapy drug?
- What is Arzerra used for and how does it work?
- How is Bendeka different to Treanda?
- Who makes Leukeran, and where is it made?
Drug information
- Rituxan Hycela Information for Consumers
- Rituxan Hycela prescribing info & package insert (for Health Professionals)
- Side Effects of Rituxan Hycela (detailed)
Related support groups
- Rituxan Hycela (2 questions, 3 members)
- Follicular Lymphoma (15 questions, 15 members)
- Diffuse Large B-Cell Lymphoma (14 questions, 3 members)
- Chronic Lymphocytic Leukemia (CLL) (26 questions, 57 members)